| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | deferasirox (Exjade®) |
| Formulation | 90 mg, 180 mg and 360 mg film-coated tablet |
| Reference number | 3395 |
| Indication | Treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. Treatment of chronic iron overload due to blood transfusions when desferrioxamine therapy is contraindicated or inadequate in the following patient groups: patients with other anaemias; patients aged 2 to 5 years; patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 14/02/2017 |